Peter Izmirly, MD
Enriched profileProfessor, Department of Medicine, NYU Grossman School of Medicine; Co-Director, NYU Lupus Clinic · NYU Grossman School of Medicine
Peter Izmirly is Professor, Department of Medicine, NYU Grossman School of Medicine; Co-Director, NYU Lupus Clinic at NYU Grossman School of Medicine. OpenAlex indexes 214 publications with 12,218 citations (h-index 49); ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Peter Izmirly, MD, is Professor, Department of Medicine, NYU Grossman School of Medicine. The public record shows 214 publications with 12,218 citations (h-index 49), centered on Lupus (SLE). It also documents an investigator role on 1 registered clinical trials, industry payments reported by 1 companies, 4 NIH-funded awards (2017–2025).
- Most recent indexed publication: 2026 · Lupus science & medicine
- Top research focus: Lupus (SLE)
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 23 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
Sponsor: NYU Langone Health
Industry payments
Updated 27 Aug 2026
1 company reported payments to CMS in program years 2021–2021. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20211 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
29.2%Folate Analog Metabolic Inhibitor20.1%Methotrexate100%Part D<11 patientsTNF inhibitor9%Enbrel Sureclick100%Part D<11 patientsAntiparasitic
26.4%Antimalarial26.4%Hydroxychloroquine Sulfate100%Part D<11 patientsMusculoskeletal
23.6%Nonsteroidal Anti-inflammatory Drug13.2%Diclofenac Sodium100%Part D<11 patientsMuscle Relaxant10.4%Cyclobenzaprine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2017–2025 per NIH RePORTER. The latest:
- DP22-002 HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health
New York University School of Medicine
FY2025$899,999U01DP006700 - Stopping Hydroxychloroquine In Elderly Lupus Disease (SHIELD)
New York University School of Medicine
FY2024$1,308,540R01AR082149 - DP22-002 HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health
New York University School of Medicine
FY2024$950,000U01DP006700
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Children exposed to hydroxychloroquine in utero show no signs of retinal toxicity at age 5.
Lupus science & medicine
Article2026 - Transcription factor Etv3 controls the tolerogenic function of dendritic cells.
Science (New York, N.Y.)
Article2026 - A human-mouse atlas of intrarenal myeloid cells identifies conserved disease-associated macrophages in lupus nephritis.
The Journal of experimental medicine
Article2025 - A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients.
Rheumatology (Oxford, England)
Article2025 - Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network.
Rheumatology (Oxford, England)
Article2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/peter-izmirly-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
medscape.com/viewarticle/1002123
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.com ↗ - Spotify
creators.spotify.com/pod/profile/lupus-org/episodes/The-Expert-Series-S8E1-Lupus-and-Fibromyalgia-e2te7ga
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →creators.spotify.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.nyu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.nyu.edu ↗
- Co-Director
NYU Lupus Clinic
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.nyu.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.nyu.edu ↗
Media & interviews
press, podcasts and appearances- Medscape InDiscussion podcast
"Lupus by the Numbers: What the Data Reveals" (Episode 1) - discussed SLE epidemiology as NYU Grossman School of Medicine professor and NYU Lupus Clinic co-director
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.com ↗ - Lupus Foundation of America "The Expert Series" podcast episode on Lupus and Fibromyalgia
featured alongside Dr. Kelly Corbitt
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lupus.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jill Buyon, MD
NYU Grossman School of Medicine
Jeffrey Berger, MD
NYU Grossman School of Medicine
Mark Mulligan, MD
NYU Grossman School of Medicine
David Goldfarb, MD
NYU Grossman School of Medicine